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Languishing antibiotic discovery and flourishing anti-
biotic resistance have prompted the development of
alternative untapped sources for antibiotic discov-
ery, including previously uncultured bacteria. Here,
we screen extracts from uncultured species against
Mycobacterium tuberculosis and identify lassomy-
cin, an antibiotic that exhibits potent bactericidal ac-
tivity against both growing and dormant mycobacte-
ria, including drug-resistant forms ofM. tuberculosis,
but little activity against other bacteria or mamma-
lian cells. Lassomycin is a highly basic, ribosomally
encoded cyclic peptide with an unusual structural
fold that only partially resembles that of other lasso
peptides. We show that lassomycin binds to a
highly acidic region of the ClpC1 ATPase complex
and markedly stimulates its ATPase activity without
stimulating ClpP1P2-catalyzed protein breakdown,
which is essential for viability of mycobacteria.
This mechanism, uncoupling ATPase from proteo-
lytic activity, accounts for the bactericidal activity
of lassomycin.
INTRODUCTION
The scarcity of suitable lead compounds is now the major
bottleneck in the development of novel antimicrobial drugs
(Lewis, 2013; Payne et al., 2007). In the absence of new thera-
peutic agents, the rise and spread of multidrug resistant path-
ogens will continue unchecked. Most antibiotics in use today
resulted from screening of soil actinomycetes for active com-
pounds. However, repeated exploitation of this limited resource
has led to diminishing returns, and most current efforts result in
rediscovering known compounds (Lewis, 2012). Consequently,Chemistry & Biology 21,there has been a general elimination of natural product-based
discovery in most pharmaceutical companies. Using new mi-
crobial sources of compounds could reduce the problem of re-
discovery and lead to novel antimicrobial agents. Uncultured
species of bacteria account for 99% of all microbial diversity
and by definition represent an unexploited source of secondary
metabolites (Staley and Konopka, 1985). We have developed
general methods to grow previously uncultured bacteria, based
on cultivation in diffusion chambers in their natural environ-
ments (Kaeberlein et al., 2002) and on prolonged incubation
in vitro (Buerger et al., 2012). This approach results in cultiva-
tion of up to 40% of cells from environmental samples. How-
ever, even with this alternate source, most of the effort is
expended on rediscovery of known compounds or generally
toxic ones. We reasoned that this problem could be addressed
by a species-selective approach, whereby compounds with
broad antibiotic spectra are eliminated, and only compounds
active against a specific species are considered. We chose
Mycobacterium tuberculosis as a target organism for this
approach, because few natural products are known to act
specifically against this pathogen, and therefore most of the
specific hits obtained should be new agents. There is also a
considerable medical need for novel anti-tuberculosis com-
pounds (Sacchettini et al., 2008; Zumla et al., 2013) to stem
the spread of extremely and totally drug-resistant strains of
the pathogen.
We screened extracts from a collection of soil bacteria,
obtained by in situ cultivation and by prolonged incubation,
against Mycobacterium tuberculosis and counterscreened
against Staphylococcus aureus. An intriguing antimicrobial, las-
somycin, was purified from an extract of Lentzea kentuckyensis
sp. Lassomycin is a potent bactericidal compound that targets
the ClpC1 ATPase, an essential enzyme in mycobacteria, which
normally functions in protein degradation together with the
ClpP1P2 proteolytic complex (Akopian et al., 2012). This agent
is a highly basic lasso peptide antibiotic that is encoded in the
genome and is unusual in its specificity for mycobacteria and
its mode of action.509–518, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 509
Figure 1. Structure of Lassomycin
(A) The amino acid sequence and posttranslational modifications of lasso-
mycin. Blue numbering indicates the positions of residues 1, 8, and 16.
(B) The backbone structure of lassomycin. The N and C termini are labeled.
(C) The structure of lassomycin with its side chains shown.
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Isolation of Lassomycin
A library of extracts from soil actinomycetes was screened
against M. tuberculosis. To shorten the duration of screens,
we constructed a strain constitutively expressing mCherry and
used bacterial fluorescence as the readout. This method allowed
for reliable detection of growth inhibition in 5 days. The screen
had a hit rate of 10% against M. tuberculosis. A counterscreen
against S. aureus had a hit rate of 30%, and the hit rate for
extracts specifically acting against M. tuberculosis was 2%.
One of the extracts identified that acted specifically against
M. tuberculosis was from isolate IS009804, a Lentzea kentuck-
yensis sp. (99.7% identical to L. kentuckyensis,GenBank acces-
sion number: DQ291145, by 16S rDNA). The extract was frac-
tionated by high-performance liquid chromatography (HPLC),
and a single active fraction was identified by bioassay-guided
purification. This fraction was lyophilized, leaving a white pow-
der. Analysis of this fraction with liquid chromatography-mass
spectrometry (LC-MS) indicated that a single major compound
was present ([M+H]+ = 1,880).
Structural Elucidation of Lassomycin
Preliminary nuclear magnetic resonance (NMR) studies indi-
cated that the active compound was a peptide, and further anal-
ysis revealed an Asp-Gln-Leu-Val-Gly pentapeptide sequence.
Elucidation of the entire structure proved to be quite challenging,
and multiple approaches were used. The producing strain was
cultured in a medium supplemented with D-glucose-U-13C6,
CELTONE base powder-U-13C, U-15N, and L-proline-U-13C5,
15N (Cambridge Isotope Laboratories) to produce a uniformly
labeled compound for further analysis with three-dimensional
NMR techniques; the pentapeptide sequence was used as a
search fragment in the producing strain’s genome to identify
the biosynthetic genes; and tandem mass spectrometry (MS/
MS) was used to experimentally identify the peptide’s sequence.
These combined approaches revealed that the active com-510 Chemistry & Biology 21, 509–518, April 24, 2014 ª2014 Elsevierpound, which we have named lassomycin, consists of 16 amino
acids in which the N-terminal residues form an eight-residue ring
through formation of an amide bond between the N-terminal
amine and the side chain carboxyl group of Asp8. The overall
structure resembles a lasso in which the eight-residue ring forms
the loop, and residues 9–16 form the spoke. In addition, the
C-terminal carboxyl is converted to a methyl ester (Figure 1A).
Acid hydrolysis of lassomycin, followed by derivatization with
Marfey’s reagent, and LC-MS analysis established that all of
the residues are L-amino acids.
The three-dimensional solution structure of lassomycin was
deduced from the NOE distance restraints obtained from
three-dimensional NMR data using CYANA 2.1 (Figure 1B).
Surprisingly, the solution structure of lassomycin lacks the char-
acteristic knot structure reported for other homologous lasso
peptides such as lariatin A and microcin J25 (Arnison et al.,
2013) because the C-terminal end packs tightly against the
N-terminal ring instead of passing through themacrolactam (Fig-
ure 1B; Figure S1 and Table S1 available online). Lassomycin has
four positively charged arginine side chains and no negatively
charged groups because the terminal carboxyl is esterified.
Biosynthetic Gene Cluster of Lassomycin
The resulting structure was consistent with the putative biosyn-
thetic genes identified in the producing strain’s genome. The
structural gene itself shows highest homology by BLAST to
larA in the larABCDE operon which codes for lariatin A. This
antibiotic is a prototypical member of the lasso peptide family,
which is produced by Rhodococcus jostii and inhibits cell wall
biosynthesis (Iwatsuki et al., 2006). Lasso peptides consist of
16-21 amino acids and feature a macrolactam ring formed
from a connection between the N terminus and a sidechain
carboxyl group. Lasso peptides are produced by both
Actinobacteria (Streptomyces and Rhodococcus) and Proteo-
bacteria (Escherichia, Burkholderia). Lariatin A is an 18-amino
acid peptide with an 8-residue ring that is formed between the
N-terminal glycine amino group and a glutamic acid side chain
at position 8. The larA gene encodes a precursor peptide that
is believed to be cleaved by LarD and enzymatically converted
to the mature lasso structure by LarB to produce the active
peptide. LarE exports the mature peptide. LarC’s function is
unknown, but it is necessary for antibiotic activity (Inokoshi
et al., 2012). The lariatin A precursor peptide shares only 53%
homology with the predicted lassomycin precursor, LasA. In
contrast, four other genes in the putative lassomycin operon
(Figure 2), lasB, lasC, lasD, and lasE, share high (84%–97%)
homology with the corresponding genes in the lariatin operon.
The last gene product of the lassomycin biosynthetic cluster,
LasF, is a putative O-methyltransferase that is likely responsible
for the formation of the methyl ester at the C terminus of the
mature peptide.
Lassomycin Bioactivity
Lassomycin had a minimum inhibitory concentration (MIC) of
0.8–3 mg/ml, fairly potent for a peptide, against a variety of
M. tuberculosis strains, including multidrug resistant and
extremely drug resistant isolates (Table 1).
Lassomycin was discovered in a screen designed to identify
compounds acting specifically against M. tuberculosis. WeLtd All rights reserved
lasA lasClasB lasD lasE lasF
Figure 2. The Putative Lassomycin Biosynthetic Operon
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rial species (Table 1). Lassomycin was highly active against
M. tuberculosis;Mycobacterium avium subsp. paratuberculosis,
which is a gastrointestinal pathogen of cattle and a suspected
pathogen in Crohn’s disease; and Mycobacterium smegmatis,
a soil microorganism. The compound was less active against
other actinobacteria tested, and had no activity against other
microorganisms tested (Table 1). Importantly, lassomycin was
inactive against symbionts of the humanmicrobiota that are sup-
pressed by conventional non-specific antibiotics (Dethlefsen
and Relman, 2011). The lassomycin MIC was unchanged in the
presence of 10% fetal bovine serum, indicating resistance to
serum proteases and a lack of significant protein binding. The
compound caused no lysis of erythrocytes and had low cytotox-
icity (half-maximal inhibitory concentration, 350 mg/ml) against
NIH 3T3 and HepG2 cells, perhaps due to poor penetration
into mammalian cells. Lassomycin has a minimum bactericidal
concentration (MBC) of 1–4 mg/ml against M. tuberculosis and
M. avium subsp. paratuberculosis. Lassomycin showed excel-
lent killing activity in a time-dependent assay against exponen-
tially growing cells of M. tuberculosis (Figure 3A). Thus, its
potency against M. tuberculosis is similar to that of the best ex-
isting bactericidal agent, rifampicin (Figure 3A). Stationary phase
cells ofM. tuberculosis are highly tolerant to most antibiotics; for
example, rifampicin showed a characteristic biphasic killing (Fig-
ure 3B) and a significant number of persister cells survive expo-
sure (Keren et al., 2011). In contrast, lassomycin had greater
killing activity against stationary M. tuberculosis than rifampicin
without an obvious presence of surviving persisters.
Target Identification and Mechanism of Action of
Lassomycin
To determine the target of lassomycin, resistant mutants of M.
tuberculosis were obtained by selecting colonies on nutrient
agar plates containing the compound. Mutants resistant to
16 mg/ml of lassomycin were obtained at a frequency of 3 3
107. Genome sequencing of six resistant mutants (Figure 4)
showedmutations in the clpC1 gene, which encodes the subunit
of the hexameric ATPase complex, ClpC1. It functions in protein
degradation with the two-ring protease complex, ClpP1P2, in
mycobacteria (Akopian et al., 2012; Raju et al., 2012). Together,
they form the large (26 subunit) ATP-dependent protease com-
plex, ClpC16P17P27C16, in which the ClpC1 ATPase binds pro-
tein substrates, unfolds them, and translocates them into the
ClpP1P2 central chamber for proteolysis (Akopian et al., 2012).
Because all the resistant mutants were mapped to the clpC1
gene, we tested directly if lassomycin altered either of ClpC1’s
enzymatic activities: its ability to hydrolyze ATP and to support
ATP-dependent protein breakdown by ClpP1P2 (Akopian
et al., 2012; Raju et al., 2012), a novel member of the ClpP family
of compartmentalized proteases (Lupas et al., 1997; Yu and
Houry, 2007). The cloned His6-tagged M. tuberculosis ClpC1Chemistry & Biology 21,was expressed inM. smegmatis and purified to near homogene-
ity, as described previously (Akopian et al., 2012). As expected,
ClpC1 exhibited ATPase activity and stimulated the ATP-depen-
dent degradation of the model protein substrate, casein, by the
pure ClpP1P2 protease complex, prepared as we recently
described (Akopian et al., 2012). Thus, ClpC1 catalyzes casein
translocation into the proteolytic compartment formed by
ClpP1P2. Surprisingly, in the presence of low concentrations of
lassomycin, ATP hydrolysis by ClpC1 increased up to 7- to
10-fold. This effect of lassomycin on ATP hydrolysis was highly
cooperative and showed a Hill coefficient of 2 (Figure 5A).
This strong activation by lassomycin showed an apparent Kd
of 0.41 mM, which resembles the value of its MIC against
M. tuberculosis cells. Because killing seems to result from bind-
ing to ClpC1 (see below), there is probably little or no barrier to
lassomycin’s entry into the bacteria.
This unexpected stimulation of ClpC1’s ATPase activity
initially suggested that lassomycin also activated protein
degradation by the ClpC1P1P2 protease. Such a mechanism
appeared likely in light of the discovery that the natural product
antibiotics, acyldepsipeptides (Kirstein et al., 2009), are bacteri-
cidal by binding to ClpP and inducing excessive breakdown of
cell proteins. In fact, by activating ClpP these antibiotics can
kill persisters and eradicate a chronic biofilm infection (Conlon
et al., 2013). Another antibiotic, cyclomarin A, which binds to
ClpC1, has also been proposed to cause excessive proteolysis
(Schmitt et al., 2011; Vasudevan et al., 2013). Surprisingly, how-
ever, we found that lassomycin, while markedly stimulating
the ATPase activity of ClpC1, completely eliminated its ability
to support ATP-dependent degradation of casein (Figure 5B),
and somehow uncoupled the ATPase activity of ClpC1 from pro-
teolysis. The resulting inhibition of proteolysis, while accelerating
ATP hydrolysis, represents an interesting mechanism of antibi-
otic action that should be highly deleterious to the bacteria,
because it prevents the regulated selective destruction of key
cell proteins by the ClpC1P1P2 complex.
One potential and easily testable mechanism for uncoupling of
ATP hydrolysis from protein degradation would be if lassomycin
prevented the binding of protein substrates to ClpC1. This pos-
sibility could be easily tested, because protein substrates of
ClpC1 are known to enhance its ATPase activity 2- to 3-fold
(Akopian et al., 2012). To determine whether lassomycin blocks
casein binding to ClpC1, we tested whether it decreases
the activation of ATP hydrolysis by casein. On the contrary, las-
somycin and casein had additive effects on ClpC1’s ATPase
activity (Figure 5C), and therefore, they probably bind to ClpC1
in distinct places (see below). Therefore, in the presence of the
antibiotic, ClpC1 seems to bind protein substrates normally,
but is incapable of translocating them into the proteolytic
compartment.
ClpC1 is a member of the large AAA family of ATPases that
serve a variety of key functions in animal and bacterial cells509–518, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 511
Table 1. Lassomycin Spectrum of Activity
Strains MIC (mg/ml) MIC (mM)
M. tuberculosis
H37Rv 0.78–1.56 0.41–0.83
186, susceptible clinical isolate 1.56 0.83
83, susceptible clinical isolate 1.56–3.1 0.83–1.65
84, resistant to INH, STR 1.56–3.1 0.83–1.65
85, resistant to INH, RIF 1.56–3.1 0.83–1.65
7, resistant to INH, RIF 1.56 0.83
86, resistant to INH, RIF, STR 1.56 0.83
136, resistant to INH, RIF, STR, FQ 0.78 0.41
133, resistant to INH, RIF, STR, FQ 0.78 0.41
189, resistant to INH, RIF, STR, FQ 3.1 1.65
3, resistant to INH, RIF, EMB, FQ 3.1 1.65
30, resistant to INH, RIF, EMB,
PZA, FQ
0.78 0.41
181, resistant to INH, RIF, EMB,
PZA, FQ
0.78 0.41
183, resistant to INH, RIF, STR,
EMB, PZA, FQ
3.1 1.65





M. avium subsp. paratuberculosis 0.125–0.25 0.07–0.13
M. smegmatis 0.78–2 0.41–1.06
Other actinobacteria
Propionibacterium acnes 12.5–25 6.7–13
Bifidobacterium longum 25–50 13–27
Other Gram-positive bacteria
Clostridium difficile >50 >27
Clostridium perfringens >50 >27
Lactobacillus reuteri >50 >27
Lactobacillus casei >50 >27
Streptococcus mutans >50 >27
Enterococcus faecalis >50 >27
Enterococcus faecalis VRE >50 >27
Bacillus anthracis Sterne >50 >27
Staphylococcus aureus >50 >27
Gram-negative bacteria
Bacteroides fragilis >50 >27
Escherichia coli K12 >50 >27
Klebsiella pneumoniae >50 >27
INH, isoniazid; RIF, rifampicin; STR, streptomycin; EMB, ethambutol;
PZA, pyrazinamide; FQ, resistant to at least one fluoroquinolone.
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White and Lauring, 2007). Use of lassomycin as an anti-tubercu-
losis drug would presumably not be advisable if it activated other
such ATPases. To determine whether lassomycin also affected
the activities of other AAA ATPases, we tested several purified
well-characterized bacterial and mammalian homologs. In
M. tuberculosis, ClpX, like ClpC1, supports protein degradation512 Chemistry & Biology 21, 509–518, April 24, 2014 ª2014 Elsevierby ClpP1P2; nevertheless, lassomycin had no effect on ATP hy-
drolysis by ClpX. In addition, no stimulation was observed with
the Escherichia coli ClpC1 homolog, ClpA, a component of the
E.coliClpAPprotease complex; PAN, the proteasomal activating
ATPase from the archaebacterium, Methanococcus jannaschii;
and themammalian 26Sproteasome (Figure 5D). This highly spe-
cific activation of ClpC1 is of appreciable mechanistic interest.
Somehow, binding of multiple lassomycin molecules must lead
to an accelerated ATP-ADP exchange cycle (Smith et al., 2011)
and much more rapid ATP hydrolysis by its six subunits.
Docking of Lassomycin to ClpC1
To gain further insight into the interaction of lassomycin with
ClpC1, an in silico approach was utilized. We focused on the
N-terminal region where all the lassomycin-resistant mutations
were localized. Recently, the X-ray structure of the ClpC1 N ter-
minus was solved by Vasudevan and colleagues (Vasudevan
et al., 2013). Depiction of the mutation sites in this model re-
vealed them to be close to each other on ClpC1 (Figure 6A).
Furthermore, they were all located in a highly acidic region,
which is likely to be the binding site for lassomycin based on
its four positively charged guanidinium groups. Docking (Trott
and Olson, 2010) of lassomycin onto this structure for ClpC1’s
N terminus showed that eight of the nine obtained binding sites
were in the same vicinity (Figures 6A and 6B). Analysis of the res-
idues contributing to binding indicated that Gln17, which was
altered in four of six resistant mutants (Figure 6A), is the major in-
teracting residue through hydrogen bonding. In the resistant
strains, Gln17 was mutated to an Arg or His, and the resulting
reversal of the charge should markedly reduce the tendency
for lassomycin binding. The other mutation sites, Arg21 and
particularly Pro79 are located, in most of the binding states, on
the rim of the surface area contacting the peptide (Figure 6A).
To clarify the mode of binding of lassomycin, models of the
resistant mutant forms of ClpC1 were created. Because the
actual conformations resulting from the mutations of these
various residues are not known, several variants of the models
were tested. The docking showed that the Gln17Arg mutation
has the largest impact on lassomycin binding, and all of the
four Gln17Arg mutant models showed a significant reduction in
the number of likely positions for lassomycin (Figure 6D). Two
variants of the Pro79Thr and two variants of the Arg21Ser muta-
tion also reduced binding greatly, considering a flexible back-
bone of lassomycin. Both results confirmed that Gln17 is critical
for antibiotic binding, whereas Arg21 and Pro79 appear to be
less important and might decrease binding by altering the pro-
tein’s tertiary structure. This analysis, while useful, has clear lim-
itations. For example, changes in ClpC1’s tertiary structure upon
hexamer formation or ATP hydrolysis are not considered. In fact,
AAA ATPases are highly dynamic structures (Smith et al., 2011),
and the upper loop in the Corynebacterium glutamicum ClpC
N-terminal crystal structure has a large temperature-factor
(Debye-Waller) value, indicating a flexible region (Figure 6C). In
addition, the conformation of lassomycin on the enzyme and
possible influence of water on its binding are not known. Never-
theless, the approach indicates clear differences between
wild-type and mutant structures in the likely binding site for las-
somycin (Figure 6D). In the future, it will be valuable to analyze
the crystal structure of ClpC1 with lassomycin bound toLtd All rights reserved
Figure 3. Time-Dependent Killing of M. tuberculosis mc26020 by Lassomycin
All drugs were administered at 103 MIC.
Each point represents the average of three biological replicates. Rifampicin (red circles), lassomycin (green triangles), or untreated (black squares) of exponential
(A) and stationary (B) M. tuberculosis. Dashed blue line indicates the limit of detection. The error bars represent SD.
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and its inability to support ATP-dependent proteolysis. Even
though lassomycin and substrates (casein) both activate
ATPase, casein must bind to a different site on ClpC1 because
casein could stimulate ClpC1 in the presence of lassomycin (Fig-
ure 5C). It is also unclear how lassomycin’s binding to this highly
acidic N-terminal region can allosterically regulate ClpC1’s
ATPase activity and lead to the inhibition of ClpP1P2-dependent
proteolysis. Most likely, the conformational changes induced
by lassomycin interfere with ClpC1’s association with ClpP1P2.
Because mutations in the binding region prevent killing by lasso-
mycin, this uncoupling of ATP hydrolysis from protein degrada-
tion must be responsible for its bactericidal actions.
SIGNIFICANCE
In multiple respects, lassomycin is a very unusual bacteri-
cidal antibiotic with an intriguingmechanism of action. First,
it kills mycobacteria selectively. This specificity is due to
targeting ClpC1 without affecting related hexameric AAA
ATPases. ClpC1, like ClpP1P2, is essential for viability in
mycobacteria but not in other bacteria. Second, its structure
is generated by cleavage of a ribosomal product, cyclization,
and C-terminal esterification. Third, it is an unusually basic,
16-residue lasso peptide, which even at low concentrations,
enters M. tuberculosis and binds to an acidic N-terminal
pocket on ClpC1. Fourth, it is unusual for an antibiotic to
activate rather than inhibit its target enzyme. An important
question for future research is to understand how lassomy-
cin’s binding to ClpC1 stimulates its ATPase activity but un-
couples it from ClpP1P2-dependent proteolysis. Normally,Chemistry & Biology 21,AAA ATPases, like ClpC, function by an ordered reaction
cycle involving each of its six subunits (Smith et al., 2011),
which extend loops into specific pockets on ClpP hep-
tamers. Most likely, this coupling mechanism is disrupted
by lassomycin. Fifth, although this interaction with ClpC1’s
N terminus is critical for lassomycin’s bactericidal action,
it is unclear whether cell death results from this prevention
of ClpC1-mediated breakdown of key proteins or from the
large increase in ClpC1’s activity (e.g., excessive ATP hydro-
lysis or excessive protein unfolding). Sixth, based on lasso-
mycin’s potency, which resembles or exceeds that of the
standard treatments for tuberculosis, agents with similar
effects on ClpC1 function represent promising approaches
to treat this disease and its drug-resistant forms.EXPERIMENTAL PROCEDURES
Bacterial Strains and Plasmids
M. smegmatis mc2155 was grown at 37C in Middlebrook 7H9 broth with
0.05% Tween-80 and ADC (0.5% BSA, 0.2% dextrose, 0.085% NaCl,
0.003 g catalase/1 l medium) with hygromycin (50 mg/ml) and anhydrotetracy-
cline (ATc; 100 ng/ml).M. tuberculosis strains were grown in Middlebrook 7H9
Broth (Difco) supplemented with 10% oleic acid-albumin-dextrose-catalase
(Difco) with additional supplements. The supplements for the auxotrophic
strain of M. tuberculosis mc26020 (DlysA,DpanCD; Sambandamurthy et al.,
2005) included 0.5% glycerol, 0.2% casamino acids (Amresco), 0.05% tylox-
apol, pantothenic acid (24 mg/ml), and lysine (80 mg/ml). The M. tuberculosis
strain mc26020 was transformed with a plasmid pBEN (gift from Dr. L. Ramak-
rishnan, University of Washington). Before transformation, the gene for green
fluorescent protein in the pBEN plasmid was replaced with a gene coding for
the red fluorescent protein mCherry (Shaner et al., 2004). The supplements for
M. tuberculosis clinical isolates included 0.2% glycerol and 0.05% Tween-80.
The clinical isolates were kindly provided by Dr. Clifton Barry III (NIH).509–518, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 513
Figure 4. Sequences of the Two N-Terminal
Repeat Regions of ClpC1 Mutants Resistant
to Lassomycin
Amino acid changes are indicated in red.
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plasmid, which has an inducible tetracycline promoter.
Long-Term Incubation Setup
One gram of soil sample was vortexed vigorously in 10 ml of deionized H2O for
10 min in a 50 ml conical tube. This sample was serially diluted and mixed with
molten 2% SMS agar (0.125 g casein, 0.1 g potato starch, 1 g casamino acids,
and 20 g Bacto-agar in 1 l deionized H2O) for plating at multiple densities of
colony forming units; 100 ml of these mixtures were then pipetted into flat bot-
tom 96-well plates. Plates were incubated at room temperature (22C) in a hu-
midified chamber and observed weekly with a 503 dissecting microscope.
Fermentation of Natural Isolates
Colonies of IS009804 were homogenized and transferred into a 250 ml Erlen-
meyer flask containing 40 ml of seed broth (15 g glucose, 10 g malt extract,
10 g soluble starch, 2.5 g yeast extract, 5 g casamino acids, and 0.2 g
CaCl2d2H2O per 1 l deionized H2O, pH adjusted to 7.0 before autoclaving).
The seed broth was incubated for 7 days at 28C on a rotary shaker (2.5
inch throw, 200 rpm) prior to production medium inoculation at 2.5% (v/v).
IS009804 was screened for antibiotic production after growth in a panel of
fermentation production media by removal of aliquots of the crude broths after
4 and 11 days of growth. The active fermentation production medium was R4
broth (10 g glucose, 1 g yeast extract, 0.1 g casamino acids, 3 g proline, 10 g
MgCl2d6H2O, 4 g CaCl2d2H2O, 0.2 g K2SO4, and 5.6 g TES free acid (2-[[1,3-
dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid) per 1 l
deionized H2O, pH to 7 before autoclaving). The samples were concentrated
to dryness and reconstituted in 100% DMSO. Further fermentation was per-
formed in 500 ml aliquots of R4 in 2 l tribaffled flasks for 5 days at 28C on a
rotary shaker (2.5 inch throw, 200 rpm).
Production of Uniformly Labeled [13C, 15N]Lassomycin
The spores and mycelia of IS009804 were used to inoculate 30 ml of
BioExpress-1000-CN Cell Growth medium (13C, 98%; 15N, 98%; Cambridge
Isotope Laboratories). The inoculated medium was incubated for 48 hr at
30C on a rotary shaker (200 rpm). Two percent of the inoculum from the
BioExpress medium were used to seed the modified R4 broth (10 g
D-glucose-U-13C6, 1.1 g CELTONE base powder-U-
13C, U-15N, 0.5 g L-pro-
line-U-13C5,
15N [Cambridge Isotope Laboratories]; 10 g MgCl2d6H2O, 4 g
CaCl2d2H2O, 0.2 g K2SO4, 5.6 g TES, 1% trace element solution [ATCC],
and 1 l H2O; the pH was adjusted to 7.5 before autoclaving). The culture
was incubated for 8 days at 30C on a rotary shaker (200 rpm).
Strain Identification
To determine the taxonomic identity of isolate IS009804, 16S rDNA sequence
analysis was used. Chromosomal DNA was isolated from approximately 106
cells after a 5-minute vigorous agitation in the presence of 50 mg of glass
beads and 100 ml of H2O in a 0.5 ml Eppendorf tube. PCR amplification of
nucleotide bases 20 through 710 of the gene encoding the 16S rRNA was car-
ried out using IS009804 chromosomal DNA, GoTaq Green Master Mix (Prom-
ega M7122), and universal primers Bac8F and 782R (Baker et al., 2003). PCR
thermocycler parameters included 30 cycles at 95C for 30 s, 45C for 30 s,514 Chemistry & Biology 21, 509–518, April 24, 2014 ª2014 Elsevier Ltd All rights reservedand 72C for 105 s. The amplified DNA frag-
ment was sequenced by Macrogen using primer
782R and compared by BLAST alignment to the
GenBank nucleotide collection.
Isolation of Lassomycin
The fermentation culture (4.0 l) was centrifuged for
20 min and the supernatant was decanted and the
cell pellet was extracted with acetone (2.0 l) andcentrifuged again. The acetone extract was combined with the supernatant
and HP-20 resin (75 g). This mixture was then concentrated under reduced
pressure on a rotary evaporator until all of the acetone had been removed.
The resin was first washed with water, then with 80% aqueous acetone before
eluting with acetone. Each sample was tested in aM. smegmatis bioassay. The
acetone sample contained all of the activity. The acetone solution was then
concentrated under reduced pressure to an orange oil. Hexanes were added
and the mixture was then centrifuged. The hexanes were then decanted,
tested for activity, and discarded because there was no activity. The remaining
residue was then reconstituted in 50% aqueous DMSO and the sample was
fractionated using an HPLC instrument equipped with a reversed-phase C18
column eluting with a gradient of H2O/acetonitrile/0.1% trifluoroacetic acid
(TFA) over 45 min. All fractions were tested for activity against M. smegmatis
and only one fraction was active. This fraction was lyophilized, leaving a white
powder (80 mg). Analysis of this fraction with LC-MS indicated that a major
compound was present ([MH]+ = 1,880). Subsequent searches in a natural
product database (AntiBase) did not provide in any results.
Electrospray Ionization-LC-MS Analysis
Electrospray ionization-LC-MS data were recorded on a MicroMass Q-Tof-2
spectrometer equippedwith anAgilent 1100 solvent delivery systemandanon-
line diode array detector using aPhenomenexGemini-C18 reversed phase col-
umn (50 3 2.0 mm, 3.0 mm particle size). Elution was performed with a linear
gradient using deionized water with 0.1% formic acid and CH3CN with 0.1%
formic acid as solvents A and B, respectively, at a flow rate of 0.2 ml/min.
The gradient increased from 25% to 100% of solvent B over 10 min followed
by an isocratic elution at 100% of solvent B for 7 min. Analytical and semipre-
parative chromatographywere performedonaZorbaxSB-C18 reversedphase
column (250 3 9.4 mm, 5.0 mm particle size) using a Shimadzu SCL-10AVP
HPLC system including a SPD-M10AVP diode array detector set at 254 nm.
Elution was performed with a linear gradient using deionized water with 0.1%
TFA and CH3CN with 0.1% TFA as solvents A and B, respectively, at a flow
rate of 3.0 ml/min. The gradient increased from 10% to 100% of solvent B
over 20 min followed by an isocratic elution at 100% of solvent B for 8 min.
Partial Hydrolysis of Lassomycin
The peptide was partially hydrolyzed using microwave-assisted acid hydroly-
sis. In a 1.5 ml polypropylene centrifuge tube, the sample solution contained
0.1 mg/ml peptide in 25% TFA or 3 M HCl. The sample tube was placed in
the water bath of a CEM microwave chamber (CEM Discover System; CEM)
to perform the hydrolysis. Microwave hydrolysis conditions were 80C,
300W, 32–70 min for TFA hydrolysis and 12 min for HCl hydrolysis. After the
microwave hydrolysis, samples were either dried using a SpeedVac vacuum
centrifuge (Savant), or purified or diluted 5 to 10 times by water, followed by
MS analysis.
MS/MS Sequencing and Exact Mass Determination of Partially
Hydrolyzed Lassomycin
The partially hydrolyzed lassomycin peptide was diluted five to ten times and
directly spotted (0.5 ml) onto a Bruker Daltonics MTP AnchorChip 800/384
target and air-dried; 0.5 ml of a-cyano-4-hydroxy cinnamic acid matrix solution
Figure 5. Lassomycin Effect on ClpC1
ATPase Activity and Protein Degradation
by ClpC1P1P2 Complex
(A) Lassomycin stimulates ATPase activity of
ClpC1. 32 nM of pure ClpC1 were mixed with
100 ml of the assay buffer (50 mM TrisHCl pH 7.8;
100 mM KCl; 10% glycerol; 1 mM phosphoenol-
pyruvate; 1 mM NADH; 2 units of pyruvate kinase/
lactic dehydrogenase [Sigma]; 4 mM MgCl2, and
1 mM ATP) and the ATPase activity of ClpC1 was
followed by measuring the coupled oxidation of
NADH to NAD+ spectrometrically at 340 nm.
Similar results were obtained when the ATPase
activity was measured with the malachite green
method (Geladopoulos et al., 1991). The rate of
ATPase activity in the absence of lassomycin was
taken as 100%. The apparent Kd and Hill coeffi-
cient for lassomycin activation of ClpC1 ATPase
were determined using curve fitting with classic
Hill-kinetic through a scaled Levenberg-Marquardt
algorithm; tolerance 0.0001.
(B) ClpC1 does not activate degradation of casein
by ClpP1P2 in the presence of lassomycin.
ClpP1P2 (100 nM) and ClpC1 (100 nM) were mixed in 80 ml of reaction buffer containing 50 mM potassium phosphate (pH 7.6), 100 mM KCl, 8 mM MgCl2, 5%
glycerol, 2 mM ATP, and 5 mM Z-Leu-Leu. Enzymatic activity was measured fluorometrically using FITC-casein as a substrate in the presence or absence of
10 mM of lassomycin. The rate of degradation of ClpP1P2 was taken as 100%.
(C) Lassomycin does not interfere with casein binding to ClpC1. ATPase activity of ClpC1 (32 nM) was measured as in Figure 5A in the presence or absence of
casein (10 mM) and lassomycin (1 mM). The activity of ClpC1 alone (control) was taken as 100%.
(D) Stimulation of ClpC1 ATPase activity by lassomycin is highly specific. The activities of purified ATPases from bacteria (M. tuberculosisClpX; E.coliClpA, ClpB,
and GroEL), archaea (PAN), andmouse (26S proteasome) were measured in the presence and absence of lassomycin (10 mM). ATPase activity of each ATPase in
the absence of lassomycin was taken as 100%.
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water to remove excess acids and salts. The matrix solution was prepared
by diluting 36 ml of saturated matrix solution in 0.1% TFA in 90:10 ACN:H2O
to an 800 ml final volume using 0.1% TFA in 85:15 ACN:H2O, containing
1 mM ammonium phosphate. Mass spectra were obtained in the positive
reflectron mode of ionization using a Bruker Daltonics UltrafleXtreme matrix-
assisted laser desorption/ionization (MALDI) time-of-flight (TOF)/TOF mass
spectrometer. The MS and MS/MS spectra were obtained in an automated
mode of operation; for MS/MS analysis, the collision-induced dissociation
gas was turned off. The instrument was calibrated over a mass range of
700–3,500 Da using a mixture of standard peptides.
The high-resolution exact mass MALDI-MS data of the partially hydrolyzed
peptide was collected on a Bruker 9.4T Apex-Qe Fourier transform ion cyclo-
tron resonance (FTICR; Bruker Daltonics) using the samples already spotted
on the MTP AnchorChipTM 800/384 target. The FTICR was externally cali-
brated using a mixture of standard peptides (Figure S2).
In addition, LC-MS/MS was performed as follows: the partially hydrolyzed
peptide was ZipTip (Millipore) purified and 5 ml of the resultant peptide solu-
tion was loaded onto a Waters nanoAcquity UPLC system (Waters) using a
peptide trap (180 mm 3 20 mm, Symmetry C18 nanoAcquity column; Waters)
and an analytical column (75 mm 3 150 mm, Atlantis dC18 nanoAcquity
column; Waters). Desalting on the peptide trap was achieved by flushing
the trap with 2% acetonitrile and 0.1% formic acid at 10 ml/min for 3 min.
Peptides were separated with a gradient of 2%–60% solvent B (acetonitrile
and 0.1% formic acid) over 35 min at 350 nl/min. The column was connected
to a Waters Q-TOF Premier (Waters) for electrospray ionization-MS/MS anal-
ysis. Data interpretation was completed manually to provide a proposed
peptide sequence.
NMR Spectroscopy of [13C, 15N]Lassomycin
NMR data were acquired and processed as previously described (Rea et al.,
2010; Sit et al., 2011). A Varian Inova 800-MHz spectrometer with a triple-reso-
nance HCN cold probe and pulsed field gradients was used to record spectra.
[13C, 15N]Lassomycin was dissolved in dimethyl sulfoxide-d6 (Cambridge
Isotope Laboratories), and the sample was heated to 40C for data collection.Chemistry & Biology 21,Table S2 lists the experimental parameters used to acquire the NMR spectra
for lassomycin. Tables S3 and S4 list the proton, backbone nitrogen, and car-
bon chemical shift assignments of the peptide. The 15N-HSQC (Figure S1A)
gave reasonably well-dispersed peaks, with 12 of 16 distinct backbone NH
signals observed, indicating that lassomycin holds a defined structure in solu-
tion. The backbone NH signals for Arg3, Leu5, Arg14, and Ile16 could not
be definitively assigned due to spectral overlap. Most of the proton chemical
shift assignments were made based on data from the HCCH-TOCSY,
13C-NOESYHSQC, and 15N-TOCSYHSQC experiments. Most of the carbon
and nitrogen chemical shift assignments were made based on the backbone
experiments HNCACB and CBCA(CO)NH (Sit et al., 2011).
Structure Calculations
CYANA 2.1 was used to calculate the structure of lassomycin (Gu¨ntert et al.,
1997), using NOE restraints measured from the 13C-NOESYHSQC and
15N-NOESYHSQC experiments combined with angle restraints obtained
from the HNHA experiment. The automatically assigned NOEs were cali-
brated within CYANA according to their intensities. After seven rounds of
calculation for lassomycin (10,000 steps per round), 449 cross-peak NOE
assignments and one 3JHNHa coupling constant were used in the final calcu-
lation. The structural statistics for the 20 lowest energy conformations of las-
somycin are summarized in Table S5. These conformations had no constraint
violations, a high number of long-range NOEs (61) used in the structure
calculation, a low average target function value (0.01), a low backbone
root-mean-square deviation (0.35 ± 0.10 A˚), and a low heavy atom root-
mean-square deviation (1.00 ± 0.23 A˚). All other figures were generated using
PyMOL.
Compound Spectrum, Activity
Potency was determined by measuring MIC with broth microdilution. Strains
were grown to an optical density of 0.3 at 650 nm and diluted 1:100 into fresh
media. Antibiotics were serially diluted 2-fold in 96-well plates and an equal
volume of diluted bacterial culture was added to each well. The plates were
sealed with Breathe-Easy (3M) and incubated at 37C for 14 days after which
growth was visually inspected. The MIC was the concentration of compound509–518, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 515
Figure 6. Images of a Docking Result and
Structure Evaluations
(A) Lassomycin (purple) binds at the mutation sites
in the M. tuberculosis ClpC1 N-domain (green; C
terminus in red). Mutation sites are labeled and
shown in orange.
(B) Transparent overlapping surface map shows
electrostatics, making positively charged regions
(blue) and negatively charged regions (red) visible.
Protein backbone in orange; mutant residues in
green.
(C) The temperature-factor value of the top loop of
the ClpC1N-terminus crystal structure 3WDB in-
dicates a very flexible part (red) of the molecule.
The color changes from very flexible in red to very
rigid in blue.
(D) Mutant ClpC1 model variants yield fewer
binding positions for the region of the lassomycin-
resistant mutations than the wild-type model (WT).
Docking was performed assuming a flexible (black)
or rigid (shaded) backbone of lassomycin.
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by plating cells from wells containing 23, 43, and 83 MIC concentrations of
compound. The plates were incubated for 3–4 weeks at 37C. The MBC
was the concentration of compound that decreased colony count byR99.9%.
To monitor in vitro cytotoxicity, exponentially growing NIH 3T3 and HepG2
cells in media supplemented with 10% FBS were harvested and seeded at
5,000 cells per well in a 96-well flat bottom plate (Smee et al., 2002). After
24 hr, the medium was replaced with fresh medium containing compounds
added at a 2-fold serial dilution, in a process similar to an MIC assay. After
24 and 48 hr of incubation, cell viability was measured with the CellTiter
96 Aqueous One Solution Cell Proliferation Assay (Promega), according to
manufacturer’s recommendations.
HighThroughput Screen
A frozen aliquot ofM. tuberculosismc26020 pBEN mCherry used to inoculate
(0.5%–1% inoculum) 50ml of 7H9with OADC, glycerol, casamino acids, talox-
apol, panthothenic acid, lysin, and 50 mg/ml of kanamycin. The culture was
incubated at 37C with shaking until the optical density 600 reached 0.4–
0.5. The culture was then diluted to have approximately 106 colony-forming
units per milliliter, and transferred to black, clear-bottom 96-well microplates
(Corning), and 1%–2% of the crude extracts were added to the tested wells.
Rifampicin 1 mg/ml (Sigma) was used as a positive control. The last column
of the plate was used as negative control (cell with 2 ml of DMSO). Plates
were sealed with Breathe-Easy Sealing Membrane (RPI) and were incubated
with shaking at 37C for 5–7 days. After incubation, fluorescence was
measured from the bottom using SynergyMX plate reader (BioTek) with
excitation 580 nm and emission 610 nm.
An auxotrophic strain ofM. tuberculosismc26020 (DlysA,DpanCD; Samban-
damurthy et al., 2005) expressing the red fluorescent protein mCherry was
screened against 25,600 crude extracts (3,200 strains, four fermentationmedia,
two timepoints).All crudeextractswerecounterscreenedagainstS.aureus. The
extracts showing activity against S. aureus were excluded from the screening
steps, and the resulting hit rate was 2%. To evaluate the quality of our assay,
the Z0-factor was calculated for several growth conditions. A Z0 factor between
1 and 0.9 is considered to be an excellent assay, between 0.9 and 0.7 is good,
and between 0.7 and 0.5 will benefit significantly from any improvement (Zhang
et al., 1999). The highest Z0 factor (0.8 ± 0.06) was obtained for the plates
containing 150 ml of cell culture after 5 days of incubation with shaking, so we
proceeded with these conditions for the high-throughput screening.516 Chemistry & Biology 21, 509–518, April 24, 2014 ª2014 Elsevier Ltd All rights reservedWhole-Genome Sequencing
Genomic DNA from M. tuberculosis mc26020
(DlysA DpanCD) wild-type and resistance mutants
were isolated using a previously described proto-col (Kieser et al., 2000). An Illumina single-end library was constructed and
50 base pair sequencing was conducted on an Illumina HiSeq2000 following
the manufacturer’s instructions at Biopolymers facility (Harvard Medical
School, Boston, MA). Genomes were assembled and mapped using the refer-
ence genome of H37Rv with CLC Genomics Workbench (CLC bio). Genomes
of resistance mutants were aligned with the genome of the wild-type to detect
single base-pair polymorphisms (SNPs).
The results were filtered to exclude any SNPs that had low confidence after
assembly. The remaining SNPs were verified with PCR amplification and
Sanger sequencing.
Purification of M. tuberculosis ClpC1
C-terminally 6XHis-tagged M. tuberculosis ClpC1 subunits were overex-
pressed in M. smegmatis using an ATc inducible expression system. After
overnight induction with ATc (100 ng/ml), cells were resuspended in buffer A
(50 mM TrisHCl pH 7.8, 100 mM KCl2, 10% glycerol, 1 mM ATP, and 4 mM
MgCl2), lysed by French press, and lysates were centrifuged for 1 hr at
100,0003 g. ClpC1 was isolated from the supernatant by Ni-NTA affinity chro-
matography (QIAGEN). Eluted fractions containing ClpC1 protein were pooled
and further purified by size-exclusion chromatography on Sephacryl S-300
column in buffer A. Fractions containing ClpC1 protein were concentrated
and used in the assays of ATPase activity and protein degradation.
Measurement of ATPase Activity
Two micrograms of pure ClpC1 was mixed with 100 ml of the assay buffer
(50 mM TrisHCl pH 7.8; 100 mM KCl; 10% glycerol; 1 mM phosphoenolpyr-
uvate; 1 mM NADH; 2 ml pyruvate kinase/lactic dehydrogenase [Sigma];
4 mM MgCl2, and 1 mM ATP) and the ATPase activity of ClpC1 was followed
by measuring the coupled oxidization of NADH to NAD+ spectrometrically at
340 nm.
Measurement of Casein Degradation
Assay of proteolytic activity was performed at 37C in 96 wells plate using
Plate Reader SpectraMax M5 (Molecular Devices). Wells contained 3 mg
ClpP1P2, 6 mg ClpC1, 5 mM Z-Leu-Leu, and 2–5 mg of fluorescein isothiocya-
nate (FITC)-casein in 80 ml of 50 mM phosphate buffer (pH 7.6) with 5% glyc-
erol, 100 mM KCl, 8 mM MgCl2, and 2 mM ATP. FITC-casein hydrolysis was
continuously monitored at 518 nm (Ex at 492 nm). Deviations in the measure-
ments of FITC-casein were less than 10%.
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The PyMOL Molecular Graphics System, version 1.5.0.1 (Schro¨dinger), was
used for protein depiction.
Molecule Docking
AutoDock Vina v1.1.2 was used to perform the docking runs (Trott and
Olson, 2010). The structure of the ClpC1 N-domain was obtained through
the Protein Data Bank (PDB; http://www.rcsb.org; Berman et al., 2000;
PDB entry 3WDB) and prepared using PyMol. Solvents and molecules other
than the ClpC1 N-domain were removed, and in silico mutations were intro-
duced. All structure files were validated with MolProbity 4.02 (Chen et al.,
2010). Only rotamers resulting in a clash score close to the wild-type model
(clash score <6; wild-type was 5.2) were chosen for the docking. The struc-
ture files for the ligand and the receptor were prepared with AutoDockTools
v1.5.6 (Morris et al., 2009). Preparation of the receptor molecules
(M. tuberculosis ClpC1 N-domain model and mutants) included the following
steps: addition of all hydrogens, computation of Gasteiger charges, and
merging of nonpolar hydrogens. To account for the fact that the bioactive
conformation of lassomycin is not known, its structure file was converted
with AutoDockTools in two variants: (1) all bonds were assumed rotatable,
except the closed lasso ring backbone; and (2) only side chains were rotat-
able, but the whole peptide backbone remains rigid. The search space was
restricted to the acidic half of the ClpC1 N-domain and the exhaustiveness
set to 100 (default is 8) to limit the generation of local minima in the optimi-
zation function. Computations of the docking runs were conducted on the
Harvard University Faculty of Arts and Science Research Computing Cluster
‘‘Odyssey.’’ Vina calculates a binding energy for each position it finds based
on the number of rotatable bonds allowed for the ligand and the environment
on the receptor (Trott and Olson, 2010). Hence, in the docking approach
here, a comparison of the binding energies between different receptor
models is not appropriate because the mutant models have a different pro-
tein sequence. Instead, the results were scored by the position of the docked
ligand on the receptor molecule. Human error in this evaluation was elimi-
nated by the fact that positive and negative positions showed a great dis-
tance from each other.
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